KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Non Operating Income (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Other Non Operating Income for 7 consecutive years, with -$8.2 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 273.23% to -$8.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.4 million through Dec 2025, down 839.14% year-over-year, with the annual reading at -$14.3 million for FY2025, 839.07% down from the prior year.
  • Other Non Operating Income hit -$8.2 million in Q4 2025 for Royalty Pharma, down from -$1.6 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $6.0 million in Q2 2024 to a low of -$18.3 million in Q4 2023.
  • Historically, Other Non Operating Income has averaged -$2.9 million across 5 years, with a median of -$1.7 million in 2023.
  • Biggest five-year swings in Other Non Operating Income: tumbled 4186.05% in 2022 and later surged 449.95% in 2024.
  • Year by year, Other Non Operating Income stood at -$4.8 million in 2021, then surged by 75.83% to -$1.2 million in 2022, then plummeted by 1471.5% to -$18.3 million in 2023, then surged by 88.04% to -$2.2 million in 2024, then crashed by 273.23% to -$8.2 million in 2025.
  • Business Quant data shows Other Non Operating Income for RPRX at -$8.2 million in Q4 2025, -$1.6 million in Q3 2025, and -$1.5 million in Q2 2025.